Case Studies

Challenge: Alacrita was engaged by a strategic investor to conduct initial due diligence on a new EGFR therapeutic strategy in oncology.

Challenge: Alacrita was engaged by a strategic investor to conduct initial due diligence on a novel observation and potential product opportunity in Alzheimer’s disease.

Challenge A leading private US academic institution, recognizing the need to further develop early discoveries from the university in order to facilitate industry partnerships and clinical...

Alacrita provides both in- and out-licensing support to a number of pharmaceutical and biotech organizations and companies. Below you'll find a series of case studies related to this service.

Challenge Our client specialized in the development of proprietary monoclonal antibodies directed towards novel targets for the treatment of immune-mediated and fibrotic disorders, including orphan...

Challenge A privately held specialty pharmaceutical company focused in the field of psychiatry was conducting a Phase III clinical evaluation of its new formulation (one-per-day) of a commonly...

Challenge A Spanish university spinout with an integrated platform to discover and develop new antimicrobials and adjuvants with novel mechanisms of action, was advancing a potentiator program that...

Challenge Our client was a leading UK Research Institute requiring assistance in assigning internal commercialization funding to the most promising research groups within the University. Alacrita was...

Challenge Our client was a leading UK Research Institute requiring assistance in assigning internal commercialization funding to the most promising research groups within the University. Alacrita was...

Challenge A leading UK University was developing an innovative technology to permit the creation of surface-immobilized functional RNAs in a microarray format, by transcription and ‘printing’ from...

Challenge A leading UK University was developing a ‘3-in-1’ PCR-based assay for rapid cell line verification and purity testing. The technology comprised a PCR-based assay containing novel markers...

Challenge: Alacrita provided interim chief medical officer support to an oncology company over the course of two years. The company was a developing a portfolio of first in class small molecules to...